Axiom Investors LLC DE Acquires 14,137 Shares of Axsome Therapeutics, Inc. $AXSM

Axiom Investors LLC DE raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 28.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 63,390 shares of the company’s stock after acquiring an additional 14,137 shares during the quarter. Axiom Investors LLC DE’s holdings in Axsome Therapeutics were worth $11,578,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Optiver Holding B.V. grew its position in Axsome Therapeutics by 82.3% in the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after acquiring an additional 130 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in Axsome Therapeutics in the 3rd quarter valued at $38,000. Advisory Services Network LLC bought a new position in Axsome Therapeutics in the 3rd quarter valued at $40,000. GAMMA Investing LLC grew its position in Axsome Therapeutics by 65.4% in the 4th quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock valued at $49,000 after acquiring an additional 106 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its position in shares of Axsome Therapeutics by 602.6% during the 4th quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock worth $50,000 after buying an additional 235 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Trading Up 4.5%

Shares of NASDAQ AXSM opened at $245.64 on Wednesday. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32. The stock has a market capitalization of $12.64 billion, a P/E ratio of -65.86 and a beta of 0.61. Axsome Therapeutics, Inc. has a 1-year low of $96.09 and a 1-year high of $246.41. The business has a fifty day moving average price of $205.86 and a 200 day moving average price of $179.97.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The company had revenue of $191.20 million for the quarter, compared to analysts’ expectations of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The business’s quarterly revenue was up 57.4% on a year-over-year basis. Equities research analysts expect that Axsome Therapeutics, Inc. will post -2.24 EPS for the current fiscal year.

Insider Buying and Selling

In other Axsome Therapeutics news, Director Mark Coleman sold 5,537 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $223.39, for a total value of $1,236,910.43. Following the completion of the sale, the director directly owned 29,603 shares in the company, valued at approximately $6,613,014.17. This trade represents a 15.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Herriot Tabuteau sold 49,670 shares of the stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $241.01, for a total value of $11,970,966.70. Following the completion of the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $1,742,261.29. This trade represents a 87.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 112,457 shares of company stock valued at $26,364,328 in the last 90 days. 20.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on AXSM shares. Truist Financial raised Axsome Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. UBS Group increased their price target on Axsome Therapeutics from $251.00 to $259.00 and gave the stock a “buy” rating in a research report on Friday, April 10th. Piper Sandler reissued an “overweight” rating and set a $258.00 price target on shares of Axsome Therapeutics in a research report on Monday, May 4th. Wolfe Research started coverage on Axsome Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $230.00 price target on the stock. Finally, Morgan Stanley increased their price target on Axsome Therapeutics from $217.00 to $242.00 and gave the stock an “equal weight” rating in a research report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $251.26.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.